RxDoctor Payments Data

Grainger Lanneau, MD

Gynecologic Oncology · Melbourne, FLNPI 1801983275

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,567 of the $1,929 with a category attached, or 81.2%. 10 manufacturers reported payments, led by Intuitive Surgical at 47.6% of the total. 2025 is the largest year on record at $982, 5.1 times the $194 reported in 2019. That places this record below the midpoint for gynecologic oncology clinicians in FL, where the typical reported total is $2,602.

$1,929in general payments, 2019–2025

Across 21 payments — averaging $91.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$918
  • GSK$248
  • Merck$242
  • Verastem, Inc.$138
  • AstraZeneca$117
  • Eisai Inc.$102
  • plus $164 from 4 others
$182,668in research payments, 2019–2025

Across 26 payments — averaging $7025.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alkermes, Inc.$183K

What the payments were for

  • Travel & lodging$36219%
  • Food & beverage$1,56781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,929 in reported general payments places this provider in the 45th percentile of 117 gynecologic oncology providers in Florida.

See all gynecologic oncology providers in Florida

Medicare billing

Part B allowed, 2024
$74,415
Medicare patients
101
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin40$402
Estradiol20$311
Ondansetron OdtOndansetron21$309
Prochlorperazine Maleate20$211
Letrozole13$163
Ondansetron Hcl13$34
Prednisone11$7

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →